|
WUMC Cancer and Leukemia Group B
|
5U10CA077440-15
|
$349,322
|
$66,371
|
BARTLETT, NANCY
|
WASHINGTON UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
2P30CA138292-04
|
$1,492,676
|
$14,927
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-04S1
|
$74,993
|
$750
|
Curran, Walter
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-04S2
|
$149,680
|
$1,497
|
Curran, Walter
|
EMORY UNIVERSITY
|
|
Virginia Mason Community Clinical Oncology Program
|
5U10CA035192-28
|
$607,994
|
$121,599
|
Nichols, Craig
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
VCU Minority-Based Community Clinical Oncology Program
|
3U10CA052784-22S1
|
$139,963
|
$22,394
|
Hackney, Mary
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
VCU Minority-Based Community Clinical Oncology Program
|
5U10CA052784-22
|
$399,112
|
$63,858
|
roberts, john
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
UPSTATE CAROLINA COMMUNITY CLINICAL ONCOLOGY PROGRAM
|
2U10CA035119-28
|
$820,953
|
$164,191
|
BEARDEN, JAMES
|
SPARTANBURG REGIONAL MEDICAL CENTER
|
|
UNMC Eppley Cancer Center Support Grant
|
3P30CA036727-26S1
|
$74,440
|
$3,722
|
COWAN, KENNETH
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
UNMC Eppley Cancer Center Support Grant
|
5P30CA036727-26
|
$1,427,680
|
$71,384
|
COWAN, KENNETH
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
University of Texas SPORE in Lung Cancer
|
5P50CA070907-15
|
$2,300,000
|
$115,000
|
MINNA, JOHN
|
UNIV OF TX SW MED CTR-DALLAS
|
|
University of Rochester Cancer Center CCOP Research Base
|
5U10CA037420-28
|
$2,138,730
|
$1,047,978
|
Morrow, Gary
|
UNIVERSITY OF ROCHESTER
|
|
University of Michigan Comprehensive Cancer Center Support Grant
|
2P30CA046592-24
|
$5,694,947
|
$56,949
|
WICHA, MAX
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
University of Michigan Comprehensive Cancer Center Support Grant
|
3P30CA046592-24S1
|
$49,948
|
$499
|
WICHA, MAX
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
University of Michigan Comprehensive Cancer Center Support Grant
|
3P30CA046592-24S2
|
$74,872
|
$749
|
WICHA, MAX
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
University of Maryland Greenebaum Cancer Center Support Grant
|
5P30CA134274-05
|
$1,565,163
|
$15,652
|
CULLEN, KEVIN
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
University of Colorado Southwest Oncology Group
|
5U10CA042777-25
|
$1
|
$0
|
ELIAS, ANTHONY
|
UNIVERSITY OF COLORADO DENVER
|
|
University of California, Irvine Cancer Center Support Grant
|
3P30CA062203-17S1
|
$74,994
|
$1,500
|
MEYSKENS, FRANK
|
UNIVERSITY OF CALIFORNIA IRVINE
|
|
University of California, Irvine Cancer Center Support Grant
|
3P30CA062203-17S2
|
$49,998
|
$1,000
|
MEYSKENS, FRANK
|
UNIVERSITY OF CALIFORNIA IRVINE
|
|
University of California, Irvine Cancer Center Support Grant
|
5P30CA062203-17
|
$1,249,323
|
$24,986
|
MEYSKENS, FRANK
|
UNIVERSITY OF CALIFORNIA IRVINE
|
|
U10 Full Member Application Affiliated with SWOG
|
5U10CA105409-09
|
$341,201
|
$167,188
|
Kim, Edward
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Tumor -Targeting Chemotherapeutic Agents
|
5R01CA103314-21
|
$314,565
|
$314,565
|
OJIMA, IWAO
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
|
Tulane Medical/Cancer Center Minority-Based Community Clinical Oncology Program
|
1U10CA167782-01
|
$700,000
|
$91,000
|
ROBINSON, WILLIAM
|
TULANE UNIVERSITY OF LOUISIANA
|
|
Transport of Large Molecules and Viral Vectors in Tumors: Effects of Cytotoxic an
|
5R01CA098706-09
|
$278,762
|
$139,381
|
BOUCHER, YVES
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Transgenic Models for Prostate and Breast Cancer
|
ZIABC005740
|
$789,123
|
$15,782
|
Green, Jeffrey
|
CCR (NCI)
|
|
Total Synthesis and Biosynthesis of Bioactive Substances
|
5R01CA070375-16
|
$215,548
|
$107,774
|
WILLIAMS, ROBERT
|
COLORADO STATE UNIVERSITY-FORT COLLINS
|
|
TOLEDO COMMUNITY CLINICAL ONCOLOGY PROGRAM
|
5U10CA035415-29
|
$700,123
|
$98,017
|
MOWAT, REX
|
TOLEDO COMMUNITY HOSPITAL ONCOLOGY PROG
|
|
To establish the BC Cancer Agency - Vancouver Centre as a major SWOG centre
|
5U10CA142559-03
|
$131,854
|
$64,608
|
BLANKE, CHARLES
|
BRITISH COLUMBIA CANCER AGENCY
|
|
Therapeutic Targeting Agents for Ovarian Cancer
|
3R01CA115483-08S1
|
$38,683
|
$19,342
|
LAM, KIT
|
UNIVERSITY OF CALIFORNIA DAVIS
|
|
Therapeutic Targeting Agents for Ovarian Cancer
|
3R01CA115483-08S2
|
$77,226
|
$38,613
|
LAM, KIT
|
UNIVERSITY OF CALIFORNIA DAVIS
|
|
Therapeutic Targeting Agents for Ovarian Cancer
|
5R01CA115483-08
|
$310,460
|
$155,230
|
LAM, KIT
|
UNIVERSITY OF CALIFORNIA DAVIS
|
|
The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer
|
5P50CA083639-13
|
$2,227,276
|
$133,637
|
BAST, ROBERT
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
The Role of SRC-1 in Breast Cancer
|
2R01CA112403-06A1
|
$269,732
|
$67,433
|
XU, JIANMING
|
BAYLOR COLLEGE OF MEDICINE
|
|
The NFkB-dependent Secretome and Invasion/Angiogenesis in Thyroid Cancer
|
5R01CA155512-02
|
$309,469
|
$154,735
|
HAUGEN, BRYAN
|
UNIVERSITY OF COLORADO DENVER
|
|
The MB-CCOP at Boston Medical Center
|
3U10CA139519-03S1
|
$300,000
|
$48,000
|
Kachnic, Lisa
|
BOSTON MEDICAL CENTER
|
|
The MB-CCOP at Boston Medical Center
|
3U10CA139519-03S2
|
$139,989
|
$22,398
|
Kachnic, Lisa
|
BOSTON MEDICAL CENTER
|
|
The MB-CCOP at Boston Medical Center
|
5U10CA139519-03
|
$310,336
|
$49,654
|
Kachnic, Lisa
|
BOSTON MEDICAL CENTER
|
|
The Gulf Coast MBCCOP
|
3U10CA128536-05S1
|
$391,891
|
$54,865
|
BEEKER, THADDEUS
|
PROVIDENCE HOSPITAL (MOBILE, AL)
|
|
The Evaluation of Novel Therapeutics for Genitourinary Malignancies
|
ZIASC010098
|
$346,999
|
$17,350
|
Dahut, William
|
CCR (NCI)
|
|
The Brooklyn Minority-Based Community Clinical Oncology Program
|
3U10CA114671-06S1
|
$139,993
|
$27,999
|
Solomon, William
|
SUNY DOWNSTATE MEDICAL CENTER
|
|
The Brooklyn Minority-Based Community Clinical Oncology Program
|
5U10CA114671-06
|
$599,843
|
$119,969
|
Solomon, William
|
SUNY DOWNSTATE MEDICAL CENTER
|
|
The Bcl-2-p85/PI3K signaling axis
|
5R01CA140980-03
|
$384,435
|
$192,218
|
ZHANG, XIAO-KUN
|
SANFORD-BURNHAM MEDICAL RESEARCH INSTIT
|
|
Telomeres, telomerase and chemotherapy: Bench to bedside
|
5R01CA077091-09
|
$333,500
|
$333,500
|
Au, Jessie
|
OPTIMUM THERAPEUTICS, LLC
|
|
Taxol: Mechanisms of Action and Resistance
|
5R01CA077263-12
|
$402,550
|
$402,550
|
HORWITZ, SUSAN
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Targeting Notch, PI3K-AKT and Other Novel Pathways in Breast Cancer Stem Cells
|
5R01CA138197-05
|
$433,884
|
$43,388
|
CHANG, JENNY
|
METHODIST HOSPITAL RESEARCH INSTITUTE
|
|
Targeting microtubule stabilization to reduce breast tumor metastasis
|
1R01CA154624-01A1
|
$318,513
|
$159,257
|
MARTIN, STUART
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
Targeting Cell Signaling in lung cancer to enhance therapeutic efficacy
|
3P01CA116676-05S2
|
$249,999
|
$125,000
|
KHURI, FADLO
|
EMORY UNIVERSITY
|
|
Targeting CDK5 in Pancreatic Cancer: Mechanistic and Preclinical Development
|
5R01CA134767-05
|
$330,091
|
$82,523
|
NELKIN, BARRY
|
JOHNS HOPKINS UNIVERSITY
|
|
Targeted Therapy for Non Small Cell Lung Carcinoma: In vivo Feasibility Studies
|
1R43CA162629-01A1
|
$193,879
|
$48,470
|
Serrero, Ginette
|
A AND G PHARMACEUTICAL, INC.
|
|
TARGETED INTERVENTION OF BREAST ONCOGENIC PATHWAYS
|
5R01CA098473-08
|
$310,370
|
$77,593
|
SEBTI, SAID
|
H. LEE MOFFITT CANCER CTR & RES INST
|
Total relevant funding to Taxol for this search: $61,414,218
|